Aon plc (FRA:4VK)

Inozyme Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	940	1,041	738	647.5	496.8	842.2
Short-Term Investments	289	140	289	379.5	179.2	247.8
Cash & Short-Term Investments	1,229	1,181	1,027	1,027	676	1,090
Cash Growth	18.17%	14.99%	-	51.92%	-37.98%	33.25%
Accounts Receivable	4,905	3,803	3,254	3,035	3,094	3,070
Other Receivables	89	43	35	74	53	95
Receivables	4,994	3,846	3,289	3,109	3,147	3,165
Prepaid Expenses	170	135	100	109	137	111
Restricted Cash	68	44	40	42.5	47.2	41.8
Other Current Assets	21,362	18,226	17,248	16,436	15,025	14,276
Total Current Assets	27,823	23,432	21,704	20,723	19,032	18,684
Property, Plant & Equipment	1,399	1,387	1,331	1,257	1,378	1,599
Long-Term Investments	101	90	45	60	64	74
Goodwill	16,024	15,234	8,414	8,292	8,434	8,666
Other Intangible Assets	6,733	6,743	234	447	492	640
Long-Term Deferred Tax Assets	861	654	1,195	824	766	724
Long-Term Deferred Charges	187	207	195	185	179	184
Other Long-Term Assets	882	1,218	841	916	1,572	1,543
Total Assets	54,010	48,965	33,959	32,704	31,917	32,114
Accounts Payable	2,294	2,905	2,262	2,114	2,192	2,016
Short-Term Debt	501	751	597	592	665	48
Current Portion of Long-Term Debt	1,336	-	607	353	499	400
Current Portion of Leases	185	191	182	186	213	234
Current Income Taxes Payable	166	260	291	193	149	80
Current Unearned Revenue	385	280	270	250	321	296
Other Current Liabilities	22,208	18,608	17,442	16,618	15,034	14,359
Total Current Liabilities	27,075	22,995	21,651	20,306	19,073	17,433
Long-Term Debt	15,451	16,265	9,995	9,825	8,228	7,281
Long-Term Leases	705	685	651	721	818	962
Long-Term Unearned Revenue	34	30	33	37	70	76
Long-Term Deferred Tax Liabilities	363	319	115	99	401	262
Other Long-Term Liabilities	1,215	1,114	1,031	959	794	754
Total Liabilities	45,921	42,535	34,701	33,133	30,759	28,531
Common Stock	2	2	2	2	2	2
Additional Paid-In Capital	13,258	13,173	6,944	6,864	6,624	6,312
Retained Earnings	-1,574	-2,309	-3,399	-2,772	-1,694	1,042
Comprehensive Income & Other	-3,843	-4,745	-4,373	-4,623	-3,871	-3,861
Total Common Equity	7,843	6,121	-826	-529	1,061	3,495
Minority Interest	246	309	84	100	97	88
Shareholders' Equity	8,089	6,430	-742	-429	1,158	3,583
Total Liabilities & Equity	54,010	48,965	33,959	32,704	31,917	32,114
Total Debt	18,178	17,892	12,032	11,677	10,423	8,925
Net Cash (Debt)	-16,949	-16,711	-11,005	-10,650	-9,747	-7,835
Net Cash Per Share	-77.77	-78.64	-53.68	-49.95	-43.11	-33.61
Filing Date Shares Outstanding	215.63	216.03	198.3	205.14	213.94	225.98
Total Common Shares Outstanding	215.7	216.03	198.6	205.4	214.8	225.5
Working Capital	748	437	53	417	-41	1,251
Book Value Per Share	36.36	28.33	-4.16	-2.58	4.94	15.50
Tangible Book Value	-14,914	-15,856	-9,474	-9,268	-7,865	-5,811
Tangible Book Value Per Share	-69.14	-73.40	-47.70	-45.12	-36.62	-25.77
Machinery	-	547	563	536	547	495
Construction In Progress	-	137	130	109	45	155
Leasehold Improvements	-	437	430	409	425	375

Source: S&P Global Market Intelligence. Standard template. Financial Sources.